All Stories

  1. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

    Article • Diabetes Care, March 2021, American Diabetes Association

    Avivit Cahn

  2. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

    Article • Diabetes Care, December 2019, American Diabetes Association

    Avivit Cahn

  3. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes

    Article • Expert Review of Clinical Pharmacology, March 2017, Taylor & Francis

    Itamar Raz, Avivit Cahn